Mackenzie Financial Corp Boosts Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Mackenzie Financial Corp increased its position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 26.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,562,694 shares of the company's stock after buying an additional 331,462 shares during the period. Mackenzie Financial Corp owned 0.43% of Bausch Health Companies worth $12,543,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of BHC. US Bancorp DE raised its stake in Bausch Health Companies by 64.9% during the first quarter. US Bancorp DE now owns 22,365 shares of the company's stock worth $511,000 after buying an additional 8,801 shares during the last quarter. HighTower Advisors LLC raised its stake in Bausch Health Companies by 24.2% during the first quarter. HighTower Advisors LLC now owns 10,763 shares of the company's stock worth $245,000 after buying an additional 2,100 shares during the last quarter. Private Advisor Group LLC increased its stake in Bausch Health Companies by 116.6% in the first quarter. Private Advisor Group LLC now owns 26,654 shares of the company's stock valued at $609,000 after purchasing an additional 14,350 shares in the last quarter. BlackRock Inc. increased its stake in Bausch Health Companies by 8.9% in the first quarter. BlackRock Inc. now owns 183,039 shares of the company's stock valued at $4,183,000 after purchasing an additional 14,908 shares in the last quarter. Finally, Blair William & Co. IL increased its stake in Bausch Health Companies by 14.7% in the first quarter. Blair William & Co. IL now owns 82,735 shares of the company's stock valued at $1,890,000 after purchasing an additional 10,590 shares in the last quarter. Institutional investors own 78.65% of the company's stock.

Wall Street Analysts Forecast Growth

BHC has been the subject of several research analyst reports. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Wednesday, February 7th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $12.00 price target on shares of Bausch Health Companies in a research note on Friday, April 12th. Finally, Jefferies Financial Group decreased their price target on shares of Bausch Health Companies from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, February 20th.

Bausch Health Companies Price Performance

Shares of NYSE BHC traded up $0.09 during mid-day trading on Friday, reaching $8.69. 2,945,834 shares of the company's stock traded hands, compared to its average volume of 3,955,018. The stock has a market cap of $3.18 billion, a P/E ratio of -5.36 and a beta of 0.85. The business has a 50-day simple moving average of $9.29 and a 200 day simple moving average of $8.15. Bausch Health Companies Inc. has a 1-year low of $5.57 and a 1-year high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.14. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The firm had revenue of $2.41 billion during the quarter, compared to analysts' expectations of $2.29 billion. During the same period last year, the company earned $1.02 earnings per share. The business's revenue was up 9.8% on a year-over-year basis. Equities research analysts anticipate that Bausch Health Companies Inc. will post 3.95 earnings per share for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.